ShortsWell not much happening here during middle of summer. We continue to eagerly wait for the 3rd party data review of phase 2 trial. I have noticed a difference in trading the past 5 days. The volume is much lower and both CIBC and Scotiabank have disappeared on the sell side. We seem to be holding the $2.08-$2.10 range.
I believe it is still premature to think the shorts have moved on but my fingers are crossed that this in fact is the case.
The third party data is long overdue, I wonder if management is holding back the data to release it with start of the next trial in the fall.
I still cannot understand how we did not get a major gap up to $7-10 range from the last 3 new releases, they were major catalysts.
1. $5M in government grants which eliminated any need for dilution to fund next trial in the fall.
2. Increased Dosage Trial produced positive results which will enhance future data from trials
3. FDA approval for phase 2 AKI trial to commence in the fall.
This stock is coiling to explode and may be your last chance to see the share price below $10 on it way to $50+